Drugs / EMUGROBART
EMUGROBART
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07137585 | Sep 2025 → Sep 2026 expected | obesity disorder, type 2 diabetes mellitus | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04708847 | Feb 2021 → Jun 2022 | — | Chugai Pharmaceutical | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06965413 | May 2025 → Aug 2026 overdue | obesity disorder | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05548556 | Feb 2023 → May 2025 overdue | facioscapulohumeral muscular dystrophy | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT05115110 | Jun 2022 → Oct 2026 expected | spinal muscular atrophy | Hoffmann-La Roche | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EMUGROBART | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068245 ↗ |
| Known as | GYM329 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04708847 ↗ |
| Known as | RG-6237 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068245 ↗ |
| Known as | RG-70240 | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068245 ↗ |
| Known as | RO7204239 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06965413 ↗ |
| Modality | Monoclonal antibody | “a humanized monoclonal antibody that binds to human latent myostatin” NCT05548556 ↗ |
| Route | Subcutaneous | “GYM329 subcutaneous injection” NCT04708847 ↗ |